hydroxychloroquine has been researched along with Colorectal Cancer in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 9.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| "In metastatic colorectal cancer (mCRC), regorafenib (RGF), a multi-kinase inhibitor with angiogenic inhibition has modest effects on survival." | 9.51 | Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). ( Arora, SP; Curiel, T; Liu, Q; Mahalingam, D; Mendez, JA; Michalek, J; Morris, J; Sarantopoulos, J; Tenner, L, 2022) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 7.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 5.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| "In metastatic colorectal cancer (mCRC), regorafenib (RGF), a multi-kinase inhibitor with angiogenic inhibition has modest effects on survival." | 5.51 | Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). ( Arora, SP; Curiel, T; Liu, Q; Mahalingam, D; Mendez, JA; Michalek, J; Morris, J; Sarantopoulos, J; Tenner, L, 2022) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 3.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karasic, TB | 1 |
| Brown, TJ | 1 |
| Schneider, C | 1 |
| Teitelbaum, UR | 1 |
| Reiss, KA | 1 |
| Mitchell, TC | 1 |
| Massa, RC | 1 |
| O'Hara, MH | 1 |
| DiCicco, L | 1 |
| Garcia-Marcano, L | 1 |
| Amaravadi, RK | 1 |
| O'Dwyer, PJ | 1 |
| Arora, SP | 1 |
| Tenner, L | 1 |
| Sarantopoulos, J | 2 |
| Morris, J | 1 |
| Liu, Q | 1 |
| Mendez, JA | 1 |
| Curiel, T | 2 |
| Michalek, J | 2 |
| Mahalingam, D | 2 |
| Jing, Z | 1 |
| Sui, X | 2 |
| Yao, J | 2 |
| Xie, J | 2 |
| Jiang, L | 2 |
| Zhou, Y | 1 |
| Pan, H | 2 |
| Han, W | 2 |
| Xie, B | 1 |
| Li, Y | 1 |
| Zhou, X | 1 |
| Patel, S | 1 |
| Hurez, V | 1 |
| Nawrocki, ST | 1 |
| Goros, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer[NCT03215264] | Phase 1 | 20 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)[NCT02316340] | Phase 2 | 44 participants (Actual) | Interventional | 2015-02-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were evaluable for toxicity if they have taken one dose of HCQ and one dose of entinostat. To be considered for evaluability in a Phase I cohort in the absence of dose-limiting toxicity, patients should have completed > 85% of HCQ doses, and at least 3 of 4 entinostat doses. The MTD will be defined as a) the dose producing DLT in 1 out of 6 patients, or b) the dose level below the dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 2 out of 6 patients. DLTs will be defined by toxicity occurring during the first 4 weeks of this study. (NCT03215264)
Timeframe: 18 months
| Intervention | mg (Number) | |
|---|---|---|
| Hydroxychloroquine Daily | Entinostat weekly | |
| All Participants | 1200 | 5 |
2 trials available for hydroxychloroquine and Colorectal Cancer
| Article | Year |
|---|---|
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colorectal Neop | 2022 |
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Colorectal Neoplasms; Humans; Hydroxychlo | 2022 |
3 other studies available for hydroxychloroquine and Colorectal Cancer
| Article | Year |
|---|---|
SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKIIγ/AKT-mediated pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy | 2016 |
Therapeutic effect of hydroxychloroquine on colorectal carcinogenesis in experimental murine colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Cell Proliferation; Colitis; Color | 2016 |
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color | 2016 |